Virta Health sees better results in pancreatic cancer study

Virta Health reports promising Phase II results showing that its supervised nutrition therapy may improve survival and quality of life for patients with advanced pancreatic cancer, offering a potential new complement to standard chemotherapy treatments.

Virta Health has revealed encouraging results from its Phase II randomized controlled trial evaluating the effects of its medically supervised nutrition therapy on patients diagnosed with stage IV metastatic pancreatic cancer. The study was conducted in collaboration with prominent medical institutions, including Mayo Clinic, HonorHealth, and the Norris Cancer Center at the University of Southern California.

Study Design and Participants

The trial involved patients receiving a combination chemotherapy regimen of nab-paclitaxel, cisplatin, and gemcitabine. Participants were randomly assigned to either Virta Health’s nutrition therapy program or a standard dietary plan, enabling a direct comparison between the effects of the specialized nutritional intervention and conventional diet alongside chemotherapy.

Key Results

The findings demonstrated that patients following the nutrition therapy program experienced a notable improvement in outcomes. Life expectancy for these patients increased by an average of 13 months, compared to the 10 months observed in the standard diet group, representing a 34% extension. Progression-free survival also improved, showing a 37% increase in the nutrition therapy cohort. These results indicate that the intervention may extend lifespan without additional toxicity or reduction in quality of life.

Feasibility and Safety

The trial confirmed that implementing a structured nutrition therapy program is feasible for patients with advanced pancreatic cancer. The intervention did not introduce additional health risks and was well-tolerated, preserving patient quality of life while supporting enhanced treatment outcomes.

Approach and Methodology

Virta Health’s program integrates:

• Individualized nutrition plans tailored to each patient’s medical profile
• Continuous monitoring and guidance from medical professionals
• AI-driven tools for personalized dietary recommendations

This approach differs from typical weight loss or diet-focused applications, as it targets the reversal of metabolic conditions such as type 2 diabetes and obesity using evidence-based nutritional strategies.

CEO Statement

Virta Health CEO Sami Inkinen emphasized the importance of these results, stating that nutrition plays a critical role in managing metabolic diseases and associated conditions. The study’s findings suggest that Virta Health’s approach may also impact the treatment of severe illnesses like metastatic pancreatic cancer, offering a potential new avenue for improving patient outcomes.

Implications for Future Research

The positive outcomes from this trial support further exploration of nutritional therapy as a complementary intervention in pancreatic cancer treatment. Structured dietary programs may enhance conventional therapies, extend survival, and maintain quality of life, highlighting the need for continued clinical investigation.

Summary

Overall, the Phase II trial demonstrates that medically supervised nutrition therapy is both safe and effective for patients with advanced pancreatic cancer. By combining individualized dietary guidance, AI-supported planning, and ongoing medical oversight, Virta Health’s approach has the potential to complement traditional chemotherapy, improve survival metrics, and enhance patient well-being.

Sources:

• Virta Health Sees Better Results in Pancreatic Cancer Study - Business Insider
• Virta Health's Trial Shows Promising Results for Pancreatic Cancer Patients - Forbes
• Virta Health's Nutritional Therapy Shows Improved Outcomes in Pancreatic Cancer - Medical News Today
• Virta Health reports improved outcomes in pancreatic cancer trial